Bio-Rad Laboratories (BIO) 10-Q5 May 232023 Q1 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2023	May 01, 2023
Document Transition Report	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
City Area Code	(510)
Document Quarterly Report	true
Entity Incorporation, State or Country Code	DE
Entity File Number	1-7928
Entity Registrant Name	BIO-RAD LABORATORIES, INC.
Entity Central Index Key	0000012208
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Small Business	false
Entity Tax Identification Number	94-1381833
Entity Address, Address Line One	1000 Alfred Nobel Drive,
Entity Address, City or Town	Hercules,
Entity Address, Country	CA
Entity Address, Postal Zip Code	94547
Local Phone Number	724-7000
Entity Emerging Growth Company	false
Common Class A [Member]
Title of 12(b) Security	Class A Common Stock, Par Value $0.0001 per share
Trading Symbol	BIO
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		24,536,303
Common Class B [Member]
Title of 12(b) Security	Class B Common Stock, Par Value $0.0001 per share
Trading Symbol	BIOb
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		5,072,933

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
ASSETS:
Cash and cash equivalents	$ 464,136	$ 434,215
Short-term investments	1,387,317	1,356,457
Restricted investments	5,560	5,560
Accounts receivable, net	498,273	494,645
Inventories:
Total inventories	752,937	719,316
Prepaid expenses	120,838	124,179
Other current assets	48,191	23,604
Total current assets	3,277,252	3,157,976
Property, plant, and equipment	1,543,984	1,508,020
Less: accumulated depreciation and amortization	1,037,530	1,009,408
Property, plant and equipment, net	506,454	498,612
Operating lease right-of-use assets	174,096	180,952
Goodwill, net	407,757	406,488
Purchased intangibles, net	327,828	332,147
Other investments	8,878,514	8,830,892
Other assets	95,513	94,599
Assets	13,667,414	13,501,666
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable	160,979	135,041
Accrued payroll and employee benefits	173,913	194,790
Current maturities of long-term debt and notes payable	519	465
Income and other taxes payable	50,867	32,428
Current operating lease liabilities	36,149	36,336
Other current liabilities	167,196	169,648
Total current liabilities	589,623	568,708
Long-term debt, net of current maturities	1,198,005	1,197,716
Deferred income taxes	1,769,781	1,770,481
Operating lease liabilities	147,040	153,597
Other long-term liabilities	199,249	195,912
Total liabilities	3,903,698	3,886,414
Stockholders' equity:
Additional paid-in capital	463,402	447,454
Retained earnings	9,966,959	9,898,203
Accumulated other comprehensive loss	(408,352)	(466,822)
Total stockholders' equity	9,763,716	9,615,252
Total liabilities and stockholders' equity	13,667,414	13,501,666
Common Class A [Member]
Stockholders' equity:
Common stock	2	2
Common Class B [Member]
Stockholders' equity:
Common stock	1	1
Treasury Class A [Member]
Stockholders' equity:
Treasury stock	$ (258,296)	$ (263,586)

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets Parenthetical - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accounts receivable allowance for doubtful accounts	$ 15,213	$ 15,029
Cash and cash equivalents	$ 464,136	$ 434,215
Common Class A [Member]
Common Stock, Shares, Issued	25,162,073	25,162,075
Common Stock, Shares, Outstanding	24,534,434	24,521,583
Common Class B [Member]
Common Stock, Shares, Issued	5,074,130	5,074,130
Common Stock, Shares, Outstanding	5,074,130	5,074,130
Treasury Stock, Common
Treasury Stock, Common, Shares	627,639	627,639

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net sales	$ 676,844	$ 700,062
Cost of goods sold	314,427	297,427
Gross profit	362,417	402,635
Selling, general and administrative expense	225,553	196,692
Research and Development Expense	74,951	59,535
Segment profit (loss)	61,913	146,408
Interest expense	12,337	4,048
Foreign exchange (gains) losses, net	(2,347)	(2,128)
Marketable Securities, Unrealized (Gain) Loss	17,525	4,545,117
Other Nonoperating Income (Expense)	50,431	32,597
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	84,829	(4,368,032)
(Provision) benefit for income taxes	(15,867)	1,000,685
Net income attributable to Bio-Rad	$ 68,962	$ (3,367,347)
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ 2.33	$ (112.50)
Weighted average common shares - basic	29,596	29,933
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ 2.32	$ (112.50)
Weighted average common shares - diluted	29,747	29,933

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net Income (Loss) Attributable to Parent	$ 68,962	$ (3,367,347)
Foreign currency translation adjustments	55,219	(128,598)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent	33	325
Net unrealized holding gains (losses) on available-for-sale investments net of tax expense	3,218	(4,030)
Total other comprehensive income (loss) net of tax	58,470	(132,303)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ 127,432	$ (3,499,650)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Cash received from customers	$ 677,522	$ 649,993
Cash paid to suppliers and employees	(552,990)	(615,630)
Interest paid, net	(22,482)	(306)
Income tax payments, net	(13,283)	(14,324)
Investment proceeds and miscellaneous receipts, net	14,662	20,680
Proceeds from forward foreign exchange contracts, net	(5,310)	10,081
Net cash provided by operating activities	98,119	50,494
Cash flows from investing activities:
Capital expenditures	(35,725)	(33,078)
Payments for purchases of marketable securities and investments	(203,588)	(960,940)
Proceeds from Sale of Debt Securities, Available-for-sale	92,751	32,096
Proceeds from maturities of marketable securities and investments	76,089	45,781
Net cash used in investing activities	(70,473)	(916,141)
Cash flows from financing activities:
Proceeds from Debt, Net of Issuance Costs	0	1,186,220
Payments on long-term borrowings	(115)	(104)
Proceeds from Issuance of Common Stock	4,424	4,177
Net cash used in financing activities	4,309	1,190,293
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(1,996)	6,877
Beginning Cash, Cash Equivalents, and Restricted Cash	434,544	471,133
Cash and cash equivalents	464,136	802,316
Restricted Cash, Current	47	14
Restricted Cash, Noncurrent	320	326
Ending Cash, Cash Equivalents, and Restricted Cash	464,503	802,656
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$ 29,959	$ 331,523

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity Statement - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common	Retained Earnings [Member]	AOCI Attributable to Parent [Member]
Total Stockholders' Equity at Dec. 31, 2021	$ 13,685,236	$ 3	$ 441,733	$ (106,290)	$ 13,525,343	$ (175,553)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	(3,367,347)	0	0	0	(3,367,347)	0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(132,303)	0	0	0	0	(132,303)
Stock Issued During Period, Value, New Issues	4,177	0	4,177	0	0	0
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	13,521	0	13,521	0	0	0
Proceeds from Issuance of Common Stock	4,177
Total Stockholders' Equity at Mar. 31, 2022	10,203,284	3	459,431	(106,290)	10,157,996	(307,856)
Total Stockholders' Equity at Dec. 31, 2022	9,615,252	3	447,454	(263,586)	9,898,203	(466,822)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	68,962	0	0	0	68,962	0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	58,470	0	0	0	0	58,470
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	16,608	0	16,608	0	0	0
Proceeds from Issuance of Common Stock	4,424
Stock Issued During Period, Value, Treasury Stock Reissued	4,424	0	(660)	5,290	(206)	0
Total Stockholders' Equity at Mar. 31, 2023	$ 9,763,716	$ 3	$ 463,402	$ (258,296)	$ 9,966,959	$ (408,352)

1. Basis of Presentation and Us

1. Basis of Presentation and Use of Estimates	3 Months Ended
1. Basis of Presentation and Use of Estimates	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies	BASIS OF PRESENTATION AND USE OF ESTIMATES Basis of Presentation In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2022. We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions. Use of Estimates The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of intangible assets, valuation of accounts receivable, estimation of warranty reserve, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates. Revenue Recognition We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is allocated between separate performance obligations of an arrangement based on the stand-alone selling price (“SSP”) for each distinct product or service. We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed. At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately. We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Our reagent rental agreements provide our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification as operating or sales-type lease. The lease term used in performing the lease classification test, includes the noncancellable period of the lease together with those periods covered by lease extension options if the customer is reasonably certain to exercise that option, the periods covered by lease termination options if the customer is reasonably certain to not exercise that option, and the periods covered by the option to extend (or to not terminate) the lease when exercise of such option is controlled by the Company. The assessment of the lease term for reagent rental agreements, including the impact from any associated contractual termination penalties, is subject to an estimation process. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel the agreement, the period in which the contract is enforceable is very short so the lease term has been limited to the noncancellable period. Generally, these arrangements do not contain an option for the lessee to purchase the underlying asset. We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After we have allocated the transaction price to the lease and non-lease elements, the amount of variable payments allocated to such elements are recognized as income in accordance with ASC 842 or ASC 606, as applicable. Maintenance services, along with the reagents, are allocated to the non-lease elements and recognized as income over time as control is transferred. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial and we do not enter into direct finance leases. Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% and 2% of total revenue for the three months ended March 31, 2023 and March 31, 2022, respectively. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss). Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss). Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region (in millions): Three Months Ended March 31, 2023 2022 United States 297.0 282.5 EMEA 204.8 218.9 APAC 135.8 160.9 Other (primarily Canada and Latin America) 39.2 37.8 Total net sales $ 676.8 $ 700.1 The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 12). Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at March 31, 2023 and December 31, 2022 was $75.3 million and $71.9 million, respectively. The short-term deferred revenue balance at March 31, 2023 and December 31, 2022 was $56.9 million and $52.2 million, respectively. We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss). Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for three months ended March 31, 2023 and 2022 were as follows (in millions): Three Months Ended March 31, 2023 2022 Balance at beginning of period $ 10.6 $ 12.7 Provision for warranty 2.0 2.2 Actual warranty costs (2.7) (2.7) Balance at end of period $ 9.9 $ 12.2 Accounts Receivable and Allowance for Credit Losses We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer. Changes in our allowance for credit losses were as follows (in millions): Three Months Ended March 31, 2023 2022 Balance at beginning of period $ 15.0 $ 15.1 Provision for expected credit losses 0.5 (1.8) Write-offs charged against the allowance (0.4) (0.5) Recoveries collected 0.1 0.1 Balance at end of period $ 15.2 $ 12.9 Recent Accounting Pronouncements Issued and to be Adopted There are no new accounting pronouncements recently issued or newly effective that had, or are expected to have, a material impact on the Company's condensed consolidated financial statements.

Business Combinations and Asset

Business Combinations and Asset Acquisitions	3 Months Ended
Business Combinations and Asset Acquisitions	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Mergers, Acquisitions and Dispositions Disclosures	ACQUISITIONS Curiosity Diagnostics Acquisition: As previously disclosed in Footnote 2 in our Annual Report on Form 10-K for the year ended December 31, 2022, on August 3, 2022, we acquired all equity interests of Curiosity Diagnostics, sp.z o.o. for a total consideration of $137.1 million, including the estimated fair value of contingent consideration. The contingent consideration of up to $70.0 million is payable upon achievement of certain technological development and sales-related milestones . No conditions triggering payment of the contingent consideration were met as of March 31, 2023. We finalized the purchase price allocation as of March 31, 2023. The final allocation of the payments reflects the effects of a deferred tax adjustment made during the measurement period. The adjustment resulted in a $0.4 million increase in goodwill and a $0.4 million increase in deferred tax liabilities compared to the preliminary balances reported at December 31, 2022 and had no impact on our condensed consolidated statements of income (loss) for the three months ended March 31, 2023.

2. Fair Value Measurements

2. Fair Value Measurements	3 Months Ended
2. Fair Value Measurements	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	FAIR VALUE MEASUREMENTS We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows: • Level 1: Quoted prices in active markets for identical instruments • Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) • Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2023 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 1.5 $ — $ 1.5 Time deposits — 44.0 — 44.0 Asset-backed securities — 3.1 — 3.1 U.S. government sponsored agencies — 20.7 — 20.7 Money market funds 35.9 — — 35.9 Total cash equivalents (a) 35.9 69.3 — 105.2 Restricted investments (b) 7.0 — — 7.0 Equity securities (c) 8,571.6 — — 8,571.6 Loan under the fair value option (d) — — 324.5 324.5 Available-for-sale investments: Corporate debt securities — 674.2 — 674.2 U.S. government sponsored agencies — 293.7 — 293.7 Foreign government obligations — 13.6 — 13.6 Municipal obligations — 18.0 — 18.0 Asset-backed securities — 328.1 — 328.1 Total available-for-sale investments (e) — 1,327.6 — 1,327.6 Forward foreign exchange contracts (f) — 1.4 — 1.4 Total financial assets carried at fair value $ 8,614.5 $ 1,398.3 $ 324.5 $ 10,337.3 Financial liabilities carried at fair value: Forward foreign exchange contracts (g) $ — $ 1.1 $ — $ 1.1 Contingent consideration (h) — — 36.4 36.4 Total financial liabilities carried at fair value $ — $ 1.1 $ 36.4 $ 37.5 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2022 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 21.1 $ — $ 21.1 Time deposits 5.7 — — 5.7 Asset-backed securities — 1.4 — 1.4 U.S. government sponsored agencies — 6.0 — 6.0 Money market funds 31.5 — — 31.5 Total cash equivalents (a) 37.2 28.5 — 65.7 Restricted investments (b) 6.8 — — 6.8 Equity securities (c) 8,530.4 — — 8,530.4 Loan under the fair value option (d) — — 322.6 322.6 Available-for-sale investments: Corporate debt securities — 699.3 — 699.3 U.S. government sponsored agencies — 230.7 — 230.7 Foreign government obligations — 13.5 — 13.5 Municipal obligations — 23.1 — 23.1 Asset-backed securities — 333.4 — 333.4 Total available-for-sale investments (e) — 1,300.0 — 1,300.0 Forward foreign exchange contracts (f) — 1.5 — 1.5 Total financial assets carried at fair value $ 8,574.4 $ 1,330.0 $ 322.6 $ 10,227.0 Financial liabilities carried at fair value: Forward foreign exchange contracts (g) $ — $ 6.2 $ — $ 6.2 Contingent consideration (h) — — 35.6 35.6 Total financial liabilities carried at fair value $ — $ 6.2 $ 35.6 $ 41.8 (a) Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets. (b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2023 December 31, 2022 Restricted investments $ 5.6 $ 5.6 Other investments 1.4 1.2 Total $ 7.0 $ 6.8 (c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2023 December 31, 2022 Short-term investments $ 59.7 $ 56.5 Other investments 8,511.9 8,473.9 Total $ 8,571.6 $ 8,530.4 (d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. (e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets. (f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets. (g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets. (h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. Changes in the fair value of contingent consideration are included in Selling, general and administrative expenses in our condensed consolidated statements of income (loss). Level 1 Fair Value Measurements As of March 31, 2023, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 38% of the ordinary outstanding shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of March 31, 2023. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting. The changes in fair market value of our investment in Sartorius for the three months ended March 31, 2023 was a $20.1 million loss and was recorded in our condensed consolidated statements of income (loss). Level 2 Fair Value Measurements To estimate the fair value of Level 2 debt securities as of March 31, 2023, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. Available-for-sale investments consist of the following (in millions): March 31, 2023 Amortized Unrealized Unrealized Allowances for Credit Losses Fair Short-term investments: Corporate debt securities $ 682.8 $ 0.4 $ (9.0) $ — $ 674.2 Municipal obligations 18.2 — (0.2) — 18.0 Asset-backed securities 333.4 0.3 (5.6) — 328.1 U.S. government sponsored agencies 295.9 0.2 (2.4) — 293.7 Foreign government obligations 13.8 — (0.2) — 13.6 $ 1,344.1 $ 0.9 $ (17.4) $ — $ 1,327.6 The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2023 by contractual maturity date (in millions): Amortized Estimated Fair Mature in less than one year $ 412.5 $ 409.1 Mature in one to five years 777.2 767.7 Mature in more than five years 154.4 150.8 Total $ 1,344.1 $ 1,327.6 Available-for-sale investments consist of the following (in millions): December 31, 2022 Amortized Unrealized Unrealized Allowances for Credit Losses Estimated Short-term investments: Corporate debt securities $ 709.9 $ 0.2 $ (10.8) — $ 699.3 Municipal obligations 23.4 — (0.3) — 23.1 Asset-backed securities 339.6 0.1 (6.3) — 333.4 U.S. government sponsored agencies 233.9 — (3.2) — 230.7 Foreign government obligations 13.8 — (0.3) — 13.5 Total 1,320.6 0.3 (20.9) — 1,300.0 As of March 31, 2023 there were no significant continuous unrealized losses greater than 12 months. Our evaluation of credit losses for available-for-sale debt securities included t he extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis. At March 31, 2023, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of March 31, 2023. Included in other current assets are $14.8 million and $11.6 million of interest receivable as of March 31, 2023 and December 31, 2022, respectively, primarily associated with securities in our available-for-sale investments portfolio. The interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the three months ended March 31, 2023, we have not written-off any uncollected interest receivable. As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of March 31, 2023 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the related receivables and payables, both of which are included in Foreign currency exchange (gains) losses, net in the condensed consolidated statements of income (loss). The following is a summary of our forward foreign exchange contracts (in millions): March 31, 2023 Contracts maturing in April through June 2023 to sell foreign currency: Notional value $ 719.5 Unrealized gain $ 0.2 Contracts maturing in April through June 2023 to purchase foreign currency: Notional value $ 84.9 Unrealized gain $ 0.2 Level 3 Fair Value Investments During the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh ("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of €400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity (the “Loan”). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family trust (“Trust”) from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares. Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares, that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and value appreciation right, including accrued interest are recognized in Losses from change in fair market value of equity securities and loan receivable in our condensed consolidated statements of income (loss). The overall change in fair market value reflected in Losses from change in fair market value of equity securities and loan receivable during the three months ended March 31, 2023 was $2.2 million, which includes an $8.0 million gain from the change in fair market value for the Loan offset by a $10.2 million loss from the change in fair market value of the value appreciation right. The decrease in the fair market value of the value appreciation right was due to a decline in the value of the Sartorius ordinary shares. As of March 31, 2023, the €400 million principal amount of the loan is still due on January 31, 2029. The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions): December 31, 2022 $ 322.6 Net decrease in estimated fair market value of the loan included in Gains (losses) in fair market value of equity securities and loan receivable $ (2.2) Foreign currency exchange gains (losses), net $ 4.1 March 31, 2023 $ 324.5

4. Intangible Assets, Goodwill

4. Intangible Assets, Goodwill and Other	3 Months Ended
4. Intangible Assets, Goodwill and Other	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure	GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS Changes to goodwill by segment are as follows (in millions): Life Clinical Total Balances as of December 31, 2022: Goodwill $ 333.3 $ 408.4 $ 741.7 Accumulated impairment losses (41.8) (293.4) (335.2) Goodwill, net 291.5 115.0 406.5 Acquisitions (see Note 2) — 0.4 0.4 Foreign currency adjustments — 0.9 0.9 Period increase, net — 1.3 1.3 Balances as of March 31, 2023: Goodwill 333.3 409.7 743.0 Accumulated impairment losses (41.8) (293.4) (335.2) Goodwill, net $ 291.5 $ 116.3 $ 407.8 Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions): March 31, 2023 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.0 $ 105.7 $ (92.2) $ 13.5 Know how 2.5 167.3 (156.1) 11.2 Developed product technology 12.7 211.9 (124.6) 87.3 Licenses 5.6 59.0 (39.5) 19.5 Tradenames 6.3 6.1 (4.5) 1.6 Covenants not to compete 3.0 6.4 (4.3) 2.1 Total finite-lived intangible assets 556.4 (421.2) 135.2 In-process research and development 192.6 — 192.6 Total purchased intangible assets $ 749.0 $ (421.2) $ 327.8 December 31, 2022 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.0 $ 104.7 $ (89.9) $ 14.8 Know how 2.8 166.2 (153.9) 12.3 Developed product technology 12.8 211.1 (121.6) 89.5 Licenses 5.8 59.0 (38.5) 20.5 Tradenames 6.6 6.1 (4.5) 1.6 Covenants not to compete 3.1 6.4 (4.0) 2.4 Total finite-lived intangible assets 553.5 (412.4) 141.1 In-process research and development 191.0 — 191.0 Total purchased intangible assets $ 744.5 $ (412.4) $ 332.1 Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended March 31, 2023 2022 Amortization expense $ 6.0 $ 6.3

Inventory

Inventory	3 Months Ended
Inventory	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventory	5. INVENTORY Following are the components of Inventory at March 31, 2023 and December 31, 2022 (in millions): March 31, 2023 December 31, 2022 Inventory: Raw materials $ 233.7 $ 228.8 Work in process 224.2 220.9 Finished goods 295.0 269.6 Total Inventory $ 752.9 $ 719.3

6. Statement of Cash Flows, Sup

6. Statement of Cash Flows, Supplemental Disclosures	3 Months Ended
6. Statement of Cash Flows, Supplemental Disclosures	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	SUPPLEMENTAL CASH FLOW INFORMATION The reconciliation of net income (loss) to net cash provided by operating activities is as follows (in millions): Three Months Ended March 31, 2023 March 31, 2022 Net income (loss) $ 69.0 $ (3,367.3) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 35.6 33.4 Reduction in the carrying amount of right-of-use assets 10.0 10.0 Share-based compensation 16.6 13.5 Losses from change in fair market value of equity securities and loan receivable 17.5 4,545.1 Payments for operating lease liabilities (9.9) (9.5) Increase in accounts receivable (1.4) (46.8) Increase in inventories (30.1) (35.5) Increase in other current assets (16.0) (33.8) Increase (decrease) in accounts payable and other current liabilities 8.2 (38.9) Increase in income taxes payable 10.4 7.8 Decrease in deferred income taxes (13.9) (1,027.8) Increase in other long-term liabilities 2.5 0.2 Other (0.4) 0.1 Net cash provided by operating activities $ 98.1 $ 50.5 Non-cash investing activities: Purchased property, plant and equipment $ 8.4 $ 1.5 Purchased marketable securities and investments $ 6.3 $ 13.2 Sold marketable securities and investments $ — $ 2.0

5. Long-Term Debt

5. Long-Term Debt	3 Months Ended
5. Long-Term Debt	Mar. 31, 2023
Debt Disclosure [Abstract]
Long-term Debt	. LONG-TERM DEBT The principal components of long-term debt are as follows (in millions): March 31, December 31, 3.3%, Senior Notes due 2027 $ 400.0 $ 400.0 3.7%, Senior Notes due 2032 800.0 800.0 Less unamortized discounts and debt issuance costs (12.0) (12.4) Long-term debt less unamortized discounts and debt issuance costs 1,188.0 1,187.6 Finance leases and other debt 10.5 10.6 Less current maturities (0.5) (0.5) Long-term debt $ 1,198.0 $ 1,197.7

6. Accumulated Other Comprehens

6. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes)	3 Months Ended
	Mar. 31, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	8. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income included in our condensed consolidated balance sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2023: $ (466.5) $ 10.0 $ (10.3) $ (466.8) Other comprehensive income, before reclassifications 55.4 0.1 4.0 59.5 Amounts reclassified from Accumulated other comprehensive income (loss) — (0.1) 0.2 0.1 Income tax effects (0.2) 0.1 (1.0) (1.1) Other comprehensive income, net of income taxes 55.2 0.1 3.2 58.5 Balances as of March 31, 2023: $ (411.3) $ 10.1 $ (7.1) $ (408.3) Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2022: $ (170.5) $ (10.9) $ 5.8 $ (175.6) Other comprehensive income (loss), before reclassifications (128.7) 0.4 (5.2) (133.5) Income tax effects 0.1 (0.1) 1.2 1.2 Other comprehensive income (loss), net of income taxes (128.6) 0.3 (4.0) (132.3) Balances as of March 31, 2022: $ (299.1) $ (10.6) $ 1.8 $ (307.9) All amounts reclassified out of accumulated other comprehensive income were reclassified into other income, net in the condensed consolidated statements of income. The reclassification adjustments are calculated using the specific identification method.

7. Earnings Per Share

7. Earnings Per Share	3 Months Ended
7. Earnings Per Share	Mar. 31, 2023
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS (LOSS) PER SHAREBio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B). Each share of Class A and Class B common stock participates equally in the earnings and losses of Bio-Rad, and each share is identical to the next in all respects except as follows. Class A common stock has limited voting rights compared to Class B. Each share of Class A is entitled to one tenth of a vote on most matters, whereas each share of Class B is always entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares. In contrast, no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder. We compute net income (loss) per share of Class A Common Stock (Class A) and Class B Common Stock (Class B) using the two-class method required for participating securities. Our participating securities include Class A and Class B. Each share of Class A and Class B participates equally in earnings and losses, but may not participate equally in dividend distributions. No dividends were distributed or declared during any of the periods presented. Earnings (loss) is attributable equally to each share of Class A and Class B common stock and is determined based on the weighted average number of the respective class of common stock outstanding for the three months ended March 31, 2023. Accordingly, basic earnings (loss) per share is computed by dividing net income (loss) attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options, restricted stock and performance stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings (loss) per share calculation if the effect of including such securities would be anti-dilutive. The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as follows (in thousands): Three Months Ended March 31, 2023 2022 Basic weighted average shares outstanding 29,596 29,933 Effect of potentially dilutive stock options, restricted stock and performance stock awards 151 — Diluted weighted average common shares outstanding 29,747 29,933 Anti-dilutive shares 94 550

8. Other Income and Expenses

8. Other Income and Expenses	3 Months Ended
8. Other Income and Expenses	Mar. 31, 2023
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure	. OTHER INCOME, NET Other income, net includes the following components (in millions): Three Months Ended March 31, 2023 2022 Interest and investment income $ (50.3) $ (32.2) Net realized losses on investments 0.7 — Other income (0.8) (0.4) Other income, net $ (50.4) $ (32.6)

9. Income Taxes

9. Income Taxes	3 Months Ended
9. Income Taxes	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	. INCOME TAXES Our effective income tax rate was 18.7% and 22.9% for the three months ended March 31, 2023 and 2022, respectively. The realization of deferred tax assets are dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain of our state and foreign deferred tax assets will not be realized as of March 31, 2023, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our federal, state and foreign deferred tax assets increased by $10 million for the period ended March 31, 2023 compared to the year ended December 31, 2022. Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. Our gross unrecognized tax benefits were $87.2 million and $85.5 million as of March 31, 2023 and December 31, 2022, respectively. The increase in our gross unrecognized tax benefits is primarily attributable to increases of uncertain tax accruals in various jurisdictions.

10. Segment Information Segment

10. Segment Information Segment Reporting	3 Months Ended
10. Segment Information Segment Reporting	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	SEGMENT INFORMATION Information regarding operating profit for the three months ended March 31, 2023 and 2022 is as follows (in millions): Life Clinical Other Net Sales 2023 $ 323.6 $ 352.1 $ 1.1 2022 $ 347.2 $ 351.8 $ 1.1 Operating Profit 2023 $ 35.7 $ 26.3 $ (0.1) 2022 $ 89.6 $ 57.1 $ (0.3) Segment results are presented in the same manner as we manage our business internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses and corporate overhead as directly supporting the strategies of our segments and these costs are fully allocated to our reportable segments. The following reconciles total segment profit to consolidated income (loss) before income taxes (in millions): Three Months Ended March 31, 2023 2022 Operating profit $ 61.9 $ 146.4 Interest expense (12.3) (4.0) Foreign currency exchange gains (losses), net 2.3 2.1 Change in fair market value of equity securities (17.5) (4,545.1) Other income (expense), net 50.4 32.6 Consolidated income (loss) before income taxes $ 84.8 $ (4,368.0)

11. Legal Proceedings

11. Legal Proceedings	3 Months Ended
11. Legal Proceedings	Mar. 31, 2023
Loss Contingency, Information about Litigation Matters [Abstract]
Legal Proceedings.	LEGAL PROCEEDINGSWe are a party to various claims, legal actions and complaints arising in the ordinary course of business. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

14. Restructuring Costs (Notes)

14. Restructuring Costs (Notes)	3 Months Ended
14. Restructuring Costs (Notes)	Mar. 31, 2023
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	RESTRUCTURING COSTS In February 2021, we announced our strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in EMEA and includes the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from EMEA to APAC. The restructuring plan is being implemented in phases and is expected to be substantially complete by mid-2023. The adjustments to expense recorded were primarily due to changes in the estimates of employee termination benefits. From February 2021 to March 31, 2023, total expenses were $67.3 million. The following table summarizes the activity of our February 2021 restructuring reserves (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2022: $ 1.9 $ 29.7 $ 31.6 Adjustment to expense (0.3) (1.0) (1.3) Cash payments (0.9) (6.1) (7.0) Foreign currency adjustments 0.1 0.2 0.3 Balances as of March 31, 2023: $ 0.8 $ 22.8 $ 23.6 In February 2023, management approved a new restructuring plan to implement identified opportunities to further streamline and improve operating performance. The additional restructuring activities are being implemented in phases and are expected to be substantially complete by the end of 2023. From February 2023 to March 31, 2023, total expenses were $14.9 million, representing estimated termination benefits to employees. The following table summarizes the activity of our February 2023 restructuring reserves (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2022: $ — $ — $ — Charged to expense - employee termination benefits 7.2 7.7 14.9 Cash payments (0.7) (0.8) (1.5) Foreign currency adjustments 0.1 0.2 0.3 Balances as of March 31, 2023: $ 6.6 $ 7.1 $ 13.7

13. Leases (Notes)

13. Leases (Notes)	3 Months Ended
13. Leases (Notes)	Mar. 31, 2023
13. Leases [Abstract]
Lessee, Operating Leases	15. LEASES We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 16 years, which includes our determination to exercise renewal options. We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our condensed consolidated balance sheets. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our condensed consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components. The components of lease expense were as follows (in millions): Three Months Ended March 31, 2023 2022 Operating lease cost $ 15.8 $ 14.3 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.1 Interest on lease liabilities 0.2 0.2 Total finance lease cost $ 0.3 $ 0.3 Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments. Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for the three months ended March 31, 2023 and 2022. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for the three months ended March 31, 2023 and 2022. Supplemental cash flow information related to leases was as follows (in millions): Three Months Ended March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 9.9 $ 9.5 Operating cash flows from finance leases $ 0.2 $ 0.2 Financing cash flows from finance leases $ 0.1 $ 0.1 Right-of-use assets obtained in exchange for new lease obligations: Operating leases $ 2.2 $ 5.5 Supplemental balance sheet information related to leases was as follows (in millions): March 31, 2023 December 31, 2022 Operating Leases Operating lease right-of-use assets $ 174.1 $ 181.0 Current operating lease liabilities $ 36.1 $ 36.3 Operating lease liabilities 147.0 153.6 Total operating lease liabilities $ 183.1 $ 189.9 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt and notes payable, net of current maturities (in millions): March 31, 2023 December 31, 2022 Finance Leases Property, plant and equipment, gross $ 11.9 11.9 Less: accumulated depreciation and amortization (5.6) (5.5) Property, plant and equipment, net $ 6.3 $ 6.4 Current maturities of long-term debt and notes payable $ 0.5 $ 0.5 Long-term debt, net of current maturities 10.0 10.1 Total finance lease liabilities $ 10.5 $ 10.6 March 31, 2023 December 31, 2022 Weighted Average Remaining Lease Term Operating leases - in years 7 7 Finance leases - in years 14 15 Weighted Average Discount Rate Operating leases 3.1 % 3.0 % Finance leases 6.4 % 6.3 % Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2023 (excluding the three months ended March 31, 2023) $ 31.1 $ 1.2 2024 37.1 1.2 2025 33.6 1.1 2026 26.3 1.1 2027 21.1 1.1 Thereafter 56.6 11.6 Total lease payments 205.8 17.3 Less imputed interest (22.7) (6.8) Total $ 183.1 $ 10.5 The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher turn-over.

1. Basis of Presentation and _2

1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Policies)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Credit Losses We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer. Changes in our allowance for credit losses were as follows (in millions): Three Months Ended March 31, 2023 2022 Balance at beginning of period $ 15.0 $ 15.1 Provision for expected credit losses 0.5 (1.8) Write-offs charged against the allowance (0.4) (0.5) Recoveries collected 0.1 0.1 Balance at end of period $ 15.2 $ 12.9
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Issued and to be Adopted There are no new accounting pronouncements recently issued or newly effective that had, or are expected to have, a material impact on the Company's condensed consolidated financial statements.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is allocated between separate performance obligations of an arrangement based on the stand-alone selling price (“SSP”) for each distinct product or service. We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed. At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately. We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Our reagent rental agreements provide our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification as operating or sales-type lease. The lease term used in performing the lease classification test, includes the noncancellable period of the lease together with those periods covered by lease extension options if the customer is reasonably certain to exercise that option, the periods covered by lease termination options if the customer is reasonably certain to not exercise that option, and the periods covered by the option to extend (or to not terminate) the lease when exercise of such option is controlled by the Company. The assessment of the lease term for reagent rental agreements, including the impact from any associated contractual termination penalties, is subject to an estimation process. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel the agreement, the period in which the contract is enforceable is very short so the lease term has been limited to the noncancellable period. Generally, these arrangements do not contain an option for the lessee to purchase the underlying asset. We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After we have allocated the transaction price to the lease and non-lease elements, the amount of variable payments allocated to such elements are recognized as income in accordance with ASC 842 or ASC 606, as applicable. Maintenance services, along with the reagents, are allocated to the non-lease elements and recognized as income over time as control is transferred. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial and we do not enter into direct finance leases. Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% and 2% of total revenue for the three months ended March 31, 2023 and March 31, 2022, respectively. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss). Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss). Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region (in millions): Three Months Ended March 31, 2023 2022 United States 297.0 282.5 EMEA 204.8 218.9 APAC 135.8 160.9 Other (primarily Canada and Latin America) 39.2 37.8 Total net sales $ 676.8 $ 700.1 The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 12). Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at March 31, 2023 and December 31, 2022 was $75.3
Use of Estimates, Policy	Use of Estimates The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of intangible assets, valuation of accounts receivable, estimation of warranty reserve, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates.
Subsequent Events, Policy	We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.
Basis of Accounting, Policy	In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2022.

1. Basis of Presentation and _3

1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Product Warranty Liability [Table Text Block]	We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss). Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for three months ended March 31, 2023 and 2022 were as follows (in millions): Three Months Ended March 31, 2023 2022 Balance at beginning of period $ 10.6 $ 12.7 Provision for warranty 2.0 2.2 Actual warranty costs (2.7) (2.7) Balance at end of period $ 9.9 $ 12.2

2. Fair Value Measurements (Tab

2. Fair Value Measurements (Tables)	3 Months Ended	6 Months Ended
2. Fair Value Measurements (Tables)	Mar. 31, 2023	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Debt Securities, Available-for-sale [Table Text Block]	Available-for-sale investments consist of the following (in millions): March 31, 2023 Amortized Unrealized Unrealized Allowances for Credit Losses Fair Short-term investments: Corporate debt securities $ 682.8 $ 0.4 $ (9.0) $ — $ 674.2 Municipal obligations 18.2 — (0.2) — 18.0 Asset-backed securities 333.4 0.3 (5.6) — 328.1 U.S. government sponsored agencies 295.9 0.2 (2.4) — 293.7 Foreign government obligations 13.8 — (0.2) — 13.6 $ 1,344.1 $ 0.9 $ (17.4) $ — $ 1,327.6	Available-for-sale investments consist of the following (in millions): December 31, 2022 Amortized Unrealized Unrealized Allowances for Credit Losses Estimated Short-term investments: Corporate debt securities $ 709.9 $ 0.2 $ (10.8) — $ 699.3 Municipal obligations 23.4 — (0.3) — 23.1 Asset-backed securities 339.6 0.1 (6.3) — 333.4 U.S. government sponsored agencies 233.9 — (3.2) — 230.7 Foreign government obligations 13.8 — (0.3) — 13.5 Total 1,320.6 0.3 (20.9) — 1,300.0
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Level 2 Fair Value Measurements To estimate the fair value of Level 2 debt securities as of March 31, 2023, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. Available-for-sale investments consist of the following (in millions): March 31, 2023 Amortized Unrealized Unrealized Allowances for Credit Losses Fair Short-term investments: Corporate debt securities $ 682.8 $ 0.4 $ (9.0) $ — $ 674.2 Municipal obligations 18.2 — (0.2) — 18.0 Asset-backed securities 333.4 0.3 (5.6) — 328.1 U.S. government sponsored agencies 295.9 0.2 (2.4) — 293.7 Foreign government obligations 13.8 — (0.2) — 13.6 $ 1,344.1 $ 0.9 $ (17.4) $ — $ 1,327.6 The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2023 by contractual maturity date (in millions): Amortized Estimated Fair Mature in less than one year $ 412.5 $ 409.1 Mature in one to five years 777.2 767.7 Mature in more than five years 154.4 150.8 Total $ 1,344.1 $ 1,327.6 Available-for-sale investments consist of the following (in millions): December 31, 2022 Amortized Unrealized Unrealized Allowances for Credit Losses Estimated Short-term investments: Corporate debt securities $ 709.9 $ 0.2 $ (10.8) — $ 699.3 Municipal obligations 23.4 — (0.3) — 23.1 Asset-backed securities 339.6 0.1 (6.3) — 333.4 U.S. government sponsored agencies 233.9 — (3.2) — 230.7 Foreign government obligations 13.8 — (0.3) — 13.5 Total 1,320.6 0.3 (20.9) — 1,300.0 As of March 31, 2023 there were no significant continuous unrealized losses greater than 12 months. Our evaluation of credit losses for available-for-sale debt securities included t he extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis. At March 31, 2023, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of March 31, 2023. Included in other current assets are $14.8 million and $11.6 million of interest receivable as of March 31, 2023 and December 31, 2022, respectively, primarily associated with securities in our available-for-sale investments portfolio. The interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the three months ended March 31, 2023, we have not written-off any uncollected interest receivable. As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of March 31, 2023 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the related receivables and payables, both of which are included in Foreign currency exchange (gains) losses, net in the condensed consolidated statements of income (loss). The following is a summary of our forward foreign exchange contracts (in millions): March 31, 2023 Contracts maturing in April through June 2023 to sell foreign currency: Notional value $ 719.5 Unrealized gain $ 0.2 Contracts maturing in April through June 2023 to purchase foreign currency: Notional value $ 84.9 Unrealized gain $ 0.2
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Level 3 Fair Value Investments During the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh ("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of €400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity (the “Loan”). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family trust (“Trust”) from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares. Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares, that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and value appreciation right, including accrued interest are recognized in Losses from change in fair market value of equity securities and loan receivable in our condensed consolidated statements of income (loss). The overall change in fair market value reflected in Losses from change in fair market value of equity securities and loan receivable during the three months ended March 31, 2023 was $2.2 million, which includes an $8.0 million gain from the change in fair market value for the Loan offset by a $10.2 million loss from the change in fair market value of the value appreciation right. The decrease in the fair market value of the value appreciation right was due to a decline in the value of the Sartorius ordinary shares. As of March 31, 2023, the €400 million principal amount of the loan is still due on January 31, 2029. The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions): December 31, 2022 $ 322.6 Net decrease in estimated fair market value of the loan included in Gains (losses) in fair market value of equity securities and loan receivable $ (2.2) Foreign currency exchange gains (losses), net $ 4.1 March 31, 2023 $ 324.5
Discussion of current derivative risk management	The following is a summary of our forward foreign exchange contracts (in millions): March 31, 2023 Contracts maturing in April through June 2023 to sell foreign currency: Notional value $ 719.5 Unrealized gain $ 0.2 Contracts maturing in April through June 2023 to purchase foreign currency: Notional value $ 84.9 Unrealized gain $ 0.2
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date	The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2023 by contractual maturity date (in millions): Amortized Estimated Fair Mature in less than one year $ 412.5 $ 409.1 Mature in one to five years 777.2 767.7 Mature in more than five years 154.4 150.8 Total $ 1,344.1 $ 1,327.6
Fair Value Measurements, Recurring and Nonrecurring	Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2023 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 1.5 $ — $ 1.5 Time deposits — 44.0 — 44.0 Asset-backed securities — 3.1 — 3.1 U.S. government sponsored agencies — 20.7 — 20.7 Money market funds 35.9 — — 35.9 Total cash equivalents (a) 35.9 69.3 — 105.2 Restricted investments (b) 7.0 — — 7.0 Equity securities (c) 8,571.6 — — 8,571.6 Loan under the fair value option (d) — — 324.5 324.5 Available-for-sale investments: Corporate debt securities — 674.2 — 674.2 U.S. government sponsored agencies — 293.7 — 293.7 Foreign government obligations — 13.6 — 13.6 Municipal obligations — 18.0 — 18.0 Asset-backed securities — 328.1 — 328.1 Total available-for-sale investments (e) — 1,327.6 — 1,327.6 Forward foreign exchange contracts (f) — 1.4 — 1.4 Total financial assets carried at fair value $ 8,614.5 $ 1,398.3 $ 324.5 $ 10,337.3 Financial liabilities carried at fair value: Forward foreign exchange contracts (g) $ — $ 1.1 $ — $ 1.1 Contingent consideration (h) — — 36.4 36.4 Total financial liabilities carried at fair value $ — $ 1.1 $ 36.4 $ 37.5 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2022 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 21.1 $ — $ 21.1 Time deposits 5.7 — — 5.7 Asset-backed securities — 1.4 — 1.4 U.S. government sponsored agencies — 6.0 — 6.0 Money market funds 31.5 — — 31.5 Total cash equivalents (a) 37.2 28.5 — 65.7 Restricted investments (b) 6.8 — — 6.8 Equity securities (c) 8,530.4 — — 8,530.4 Loan under the fair value option (d) — — 322.6 322.6 Available-for-sale investments: Corporate debt securities — 699.3 — 699.3 U.S. government sponsored agencies — 230.7 — 230.7 Foreign government obligations — 13.5 — 13.5 Municipal obligations — 23.1 — 23.1 Asset-backed securities — 333.4 — 333.4 Total available-for-sale investments (e) — 1,300.0 — 1,300.0 Forward foreign exchange contracts (f) — 1.5 — 1.5 Total financial assets carried at fair value $ 8,574.4 $ 1,330.0 $ 322.6 $ 10,227.0 Financial liabilities carried at fair value: Forward foreign exchange contracts (g) $ — $ 6.2 $ — $ 6.2 Contingent consideration (h) — — 35.6 35.6 Total financial liabilities carried at fair value $ — $ 6.2 $ 35.6 $ 41.8 (a) Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets. (b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2023 December 31, 2022 Restricted investments $ 5.6 $ 5.6 Other investments 1.4 1.2 Total $ 7.0 $ 6.8 (c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2023 December 31, 2022 Short-term investments $ 59.7 $ 56.5 Other investments 8,511.9 8,473.9 Total $ 8,571.6 $ 8,530.4 (d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. (e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets. (f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets. (g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets. (h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. Changes in the fair value of contingent consideration are included in Selling, general and administrative expenses in our condensed consolidated statements of income (loss). Level 1 Fair Value Measurements As of March 31, 2023, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 38% of the ordinary outstanding shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of March 31, 2023. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting. The changes in fair market value of our investment in Sartorius for the three months ended March 31, 2023 was a $20.1 million loss and was recorded in our condensed consolidated statements of income (loss).

4. Intangible Assets, Goodwil_2

4. Intangible Assets, Goodwill and Other (Tables)	3 Months Ended
4. Intangible Assets, Goodwill and Other (Tables)	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Changes to goodwill by segment	Changes to goodwill by segment are as follows (in millions): Life Clinical Total Balances as of December 31, 2022: Goodwill $ 333.3 $ 408.4 $ 741.7 Accumulated impairment losses (41.8) (293.4) (335.2) Goodwill, net 291.5 115.0 406.5 Acquisitions (see Note 2) — 0.4 0.4 Foreign currency adjustments — 0.9 0.9 Period increase, net — 1.3 1.3 Balances as of March 31, 2023: Goodwill 333.3 409.7 743.0 Accumulated impairment losses (41.8) (293.4) (335.2) Goodwill, net $ 291.5 $ 116.3 $ 407.8
Schedule of identifiable purchased intangible assets with definite lives	Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions): March 31, 2023 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.0 $ 105.7 $ (92.2) $ 13.5 Know how 2.5 167.3 (156.1) 11.2 Developed product technology 12.7 211.9 (124.6) 87.3 Licenses 5.6 59.0 (39.5) 19.5 Tradenames 6.3 6.1 (4.5) 1.6 Covenants not to compete 3.0 6.4 (4.3) 2.1 Total finite-lived intangible assets 556.4 (421.2) 135.2 In-process research and development 192.6 — 192.6 Total purchased intangible assets $ 749.0 $ (421.2) $ 327.8 December 31, 2022 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.0 $ 104.7 $ (89.9) $ 14.8 Know how 2.8 166.2 (153.9) 12.3 Developed product technology 12.8 211.1 (121.6) 89.5 Licenses 5.8 59.0 (38.5) 20.5 Tradenames 6.6 6.1 (4.5) 1.6 Covenants not to compete 3.1 6.4 (4.0) 2.4 Total finite-lived intangible assets 553.5 (412.4) 141.1 In-process research and development 191.0 — 191.0 Total purchased intangible assets $ 744.5 $ (412.4) $ 332.1
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended March 31, 2023 2022 Amortization expense $ 6.0 $ 6.3

Inventory (Tables)

Inventory (Tables)	3 Months Ended
Inventory (Tables)	Mar. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Following are the components of Inventory at March 31, 2023 and December 31, 2022 (in millions): March 31, 2023 December 31, 2022 Inventory: Raw materials $ 233.7 $ 228.8 Work in process 224.2 220.9 Finished goods 295.0 269.6 Total Inventory $ 752.9 $ 719.3

6. Supplemental Cash Flow Infor

6. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure - (Tables)	3 Months Ended
	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	The reconciliation of net income (loss) to net cash provided by operating activities is as follows (in millions): Three Months Ended March 31, 2023 March 31, 2022 Net income (loss) $ 69.0 $ (3,367.3) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 35.6 33.4 Reduction in the carrying amount of right-of-use assets 10.0 10.0 Share-based compensation 16.6 13.5 Losses from change in fair market value of equity securities and loan receivable 17.5 4,545.1 Payments for operating lease liabilities (9.9) (9.5) Increase in accounts receivable (1.4) (46.8) Increase in inventories (30.1) (35.5) Increase in other current assets (16.0) (33.8) Increase (decrease) in accounts payable and other current liabilities 8.2 (38.9) Increase in income taxes payable 10.4 7.8 Decrease in deferred income taxes (13.9) (1,027.8) Increase in other long-term liabilities 2.5 0.2 Other (0.4) 0.1 Net cash provided by operating activities $ 98.1 $ 50.5 Non-cash investing activities: Purchased property, plant and equipment $ 8.4 $ 1.5 Purchased marketable securities and investments $ 6.3 $ 13.2 Sold marketable securities and investments $ — $ 2.0

5. Long-Term Debt (Tables)

5. Long-Term Debt (Tables)	3 Months Ended
5. Long-Term Debt (Tables)	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	The principal components of long-term debt are as follows (in millions): March 31, December 31, 3.3%, Senior Notes due 2027 $ 400.0 $ 400.0 3.7%, Senior Notes due 2032 800.0 800.0 Less unamortized discounts and debt issuance costs (12.0) (12.4) Long-term debt less unamortized discounts and debt issuance costs 1,188.0 1,187.6 Finance leases and other debt 10.5 10.6 Less current maturities (0.5) (0.5) Long-term debt $ 1,198.0 $ 1,197.7

6. Accumulated Other Comprehe_2

6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2023
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Accumulated other comprehensive income included in our condensed consolidated balance sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2023: $ (466.5) $ 10.0 $ (10.3) $ (466.8) Other comprehensive income, before reclassifications 55.4 0.1 4.0 59.5 Amounts reclassified from Accumulated other comprehensive income (loss) — (0.1) 0.2 0.1 Income tax effects (0.2) 0.1 (1.0) (1.1) Other comprehensive income, net of income taxes 55.2 0.1 3.2 58.5 Balances as of March 31, 2023: $ (411.3) $ 10.1 $ (7.1) $ (408.3) Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains (losses) on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2022: $ (170.5) $ (10.9) $ 5.8 $ (175.6) Other comprehensive income (loss), before reclassifications (128.7) 0.4 (5.2) (133.5) Income tax effects 0.1 (0.1) 1.2 1.2 Other comprehensive income (loss), net of income taxes (128.6) 0.3 (4.0) (132.3) Balances as of March 31, 2022: $ (299.1) $ (10.6) $ 1.8 $ (307.9)

7. Earnings Per Share (Tables)

7. Earnings Per Share (Tables)	3 Months Ended
7. Earnings Per Share (Tables)	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares	The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as follows (in thousands): Three Months Ended March 31, 2023 2022 Basic weighted average shares outstanding 29,596 29,933 Effect of potentially dilutive stock options, restricted stock and performance stock awards 151 — Diluted weighted average common shares outstanding 29,747 29,933 Anti-dilutive shares 94 550

8. Other Income and Expenses (T

8. Other Income and Expenses (Tables)	3 Months Ended
8. Other Income and Expenses (Tables)	Mar. 31, 2023
Other Income and Expenses [Abstract]
Schedule of other income (expense), net	Other income, net includes the following components (in millions): Three Months Ended March 31, 2023 2022 Interest and investment income $ (50.3) $ (32.2) Net realized losses on investments 0.7 — Other income (0.8) (0.4) Other income, net $ (50.4) $ (32.6)

10. Segment Information Segme_2

10. Segment Information Segment Reporting (Tables)	3 Months Ended
10. Segment Information Segment Reporting (Tables)	Mar. 31, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Information regarding operating profit for the three months ended March 31, 2023 and 2022 is as follows (in millions): Life Clinical Other Net Sales 2023 $ 323.6 $ 352.1 $ 1.1 2022 $ 347.2 $ 351.8 $ 1.1 Operating Profit 2023 $ 35.7 $ 26.3 $ (0.1) 2022 $ 89.6 $ 57.1 $ (0.3)
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Segment results are presented in the same manner as we manage our business internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses and corporate overhead as directly supporting the strategies of our segments and these costs are fully allocated to our reportable segments. The following reconciles total segment profit to consolidated income (loss) before income taxes (in millions): Three Months Ended March 31, 2023 2022 Operating profit $ 61.9 $ 146.4 Interest expense (12.3) (4.0) Foreign currency exchange gains (losses), net 2.3 2.1 Change in fair market value of equity securities (17.5) (4,545.1) Other income (expense), net 50.4 32.6 Consolidated income (loss) before income taxes $ 84.8 $ (4,368.0)
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

14. Restructuring Costs (Tables

14. Restructuring Costs (Tables)	3 Months Ended
14. Restructuring Costs (Tables)	Mar. 31, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the activity of our February 2021 restructuring reserves (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2022: $ 1.9 $ 29.7 $ 31.6 Adjustment to expense (0.3) (1.0) (1.3) Cash payments (0.9) (6.1) (7.0) Foreign currency adjustments 0.1 0.2 0.3 Balances as of March 31, 2023: $ 0.8 $ 22.8 $ 23.6 The following table summarizes the activity of our February 2023 restructuring reserves (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2022: $ — $ — $ — Charged to expense - employee termination benefits 7.2 7.7 14.9 Cash payments (0.7) (0.8) (1.5) Foreign currency adjustments 0.1 0.2 0.3 Balances as of March 31, 2023: $ 6.6 $ 7.1 $ 13.7

13. Leases (Tables)

13. Leases (Tables)	3 Months Ended
13. Leases (Tables)	Mar. 31, 2023
13. Leases [Abstract]
Lease, Cost [Table Text Block]	The components of lease expense were as follows (in millions): Three Months Ended March 31, 2023 2022 Operating lease cost $ 15.8 $ 14.3 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.1 Interest on lease liabilities 0.2 0.2 Total finance lease cost $ 0.3 $ 0.3
Lessee Supplemental Cash Flow Information [Table Text Block]	Supplemental cash flow information related to leases was as follows (in millions): Three Months Ended March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 9.9 $ 9.5 Operating cash flows from finance leases $ 0.2 $ 0.2 Financing cash flows from finance leases $ 0.1 $ 0.1 Right-of-use assets obtained in exchange for new lease obligations: Operating leases $ 2.2 $ 5.5
Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]	Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2023 (excluding the three months ended March 31, 2023) $ 31.1 $ 1.2 2024 37.1 1.2 2025 33.6 1.1 2026 26.3 1.1 2027 21.1 1.1 Thereafter 56.6 11.6 Total lease payments 205.8 17.3 Less imputed interest (22.7) (6.8) Total $ 183.1 $ 10.5
Lessee Supplemental Balance Sheet Information [Table Text Block]	Supplemental balance sheet information related to leases was as follows (in millions): March 31, 2023 December 31, 2022 Operating Leases Operating lease right-of-use assets $ 174.1 $ 181.0 Current operating lease liabilities $ 36.1 $ 36.3 Operating lease liabilities 147.0 153.6 Total operating lease liabilities $ 183.1 $ 189.9 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt and notes payable, net of current maturities (in millions): March 31, 2023 December 31, 2022 Finance Leases Property, plant and equipment, gross $ 11.9 11.9 Less: accumulated depreciation and amortization (5.6) (5.5) Property, plant and equipment, net $ 6.3 $ 6.4 Current maturities of long-term debt and notes payable $ 0.5 $ 0.5 Long-term debt, net of current maturities 10.0 10.1 Total finance lease liabilities $ 10.5 $ 10.6 March 31, 2023 December 31, 2022 Weighted Average Remaining Lease Term Operating leases - in years 7 7 Finance leases - in years 14 15 Weighted Average Discount Rate Operating leases 3.1 % 3.0 % Finance leases 6.4 % 6.3 %

1. Basis of Presentation and _4

1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	$ 676,844	$ 700,062
Cost of goods sold	314,427	297,427
Deferred Revenue	75,300		$ 71,900
Retained earnings	9,966,959		9,898,203
Accumulated other comprehensive loss	(408,352)		(466,822)
Total stockholders' equity	$ 9,763,716	$ 10,203,284	9,615,252	$ 13,685,236
Revenue Allocation Percent To Lease Elements	3%	2%
Additional paid-in-capital	$ 463,402		447,454
Selling, general and administrative expense	225,553	$ 196,692
Research and Development Expense	74,951	59,535
Interest expense	12,337	4,048
Other Nonoperating Income (Expense)	50,431	32,597
Deferred Revenue, Current	56,900		$ 52,200
Europe [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	204,800	218,900
Asia Pacific [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	135,800	160,900
UNITED STATES
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	297,000	282,500
Americas [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	$ 39,200	$ 37,800

1. Basis of Presentation and _5

1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Warranty accrual, beginning of period	$ 10.6	$ 12.7
Provision for warranty	2	2.2
Actual warranty costs	(2.7)	(2.7)
Warranty accrual, end of period	$ 9.9	$ 12.2

1. Basis of Presentation and _6

1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts Receivable, Allowance for Credit Loss	$ 15.2	$ 12.9	$ 15	$ 15.1
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)	0.5	(1.8)
Allowance for Loan and Lease Losses, Write-offs	(0.4)	(0.5)
Accounts Receivable, Allowance for Credit Loss, Recovery	$ 0.1	$ 0.1

1. Basis of Presentation and _7

1. Basis of Presentation and Use of Estimates (Details)	3 Months Ended
1. Basis of Presentation and Use of Estimates (Details)	Mar. 31, 2023	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenue Allocation Percent To Lease Elements	3%	2%

Business Combinations and Ass_2

Business Combinations and Asset Acquisitions (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Aug. 03, 2022
Goodwill [Member]
Business Acquisition [Line Items]
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets	$ 0.4
Other Noncurrent Liabilities [Member]
Business Acquisition [Line Items]
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities	$ 0.4
Curiosity Diagnostics
Business Acquisition [Line Items]
Business Combination, Consideration Transferred		$ 137.1
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			$ 70

2. Fair Value Measurements Fair

2. Fair Value Measurements Fair Value Level Table (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Trading, and Equity Securities, FV-NI	[1]	$ 324.5		$ 322.6
Debt Securities, Available-for-sale	[2]	1,327.6
Fair Value, Option, Changes in Fair Value, Gain (Loss)	[1]	2.2
Foreign exchange (gains) losses, net	[1]	4.1
Fair Value, Option, Loans Held as Assets [Abstract]
Debt Securities	[1]	400
Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions		(8)
Derivative, Forward Interest Rate						1.50%
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[3]	7		6.8
Equity Securities	[4]	8,571.6		8,530.4
Debt Securities, Trading, and Equity Securities, FV-NI	[1]	324.5		322.6
Debt Securities, Available-for-sale	[2]	1,327.6		1,300
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[5]	1.4		1.5
Assets, Fair Value Disclosure		10,337.3		10,227
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[6]	1.1		6.2
Business Combination, Contingent Consideration, Liability		36.4	[7]	35.6
Liabilities, Fair Value Disclosure		37.5		41.8
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[3]	7		6.8
Equity Securities	[4]	8,571.6		8,530.4
Debt Securities, Trading, and Equity Securities, FV-NI	[1]	0		0
Debt Securities, Available-for-sale	[2]	0		0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[5]	0		0
Assets, Fair Value Disclosure		8,614.5		8,574.4
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[6]	0		0
Business Combination, Contingent Consideration, Liability		0	[7]	0
Liabilities, Fair Value Disclosure		0		0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[3]	0		0
Equity Securities	[4]	0		0
Debt Securities, Trading, and Equity Securities, FV-NI	[1]	0		0
Debt Securities, Available-for-sale		1,327.6		1,300	[2]
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[5]	1.4		1.5
Assets, Fair Value Disclosure		1,398.3		1,330
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[6]	1.1		6.2
Business Combination, Contingent Consideration, Liability		0	[7]	0
Liabilities, Fair Value Disclosure		1.1		6.2
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[3]	0		0
Equity Securities	[4]	0		0
Debt Securities, Trading, and Equity Securities, FV-NI	[1]	324.5		322.6
Debt Securities, Available-for-sale	[2]	0		0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[5]	0		0
Assets, Fair Value Disclosure		324.5		322.6
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[6]	0		0
Business Combination, Contingent Consideration, Liability		36.4	[7]	35.6
Liabilities, Fair Value Disclosure		36.4		35.6
Asset-backed Securities [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	3.1		1.4
Asset-backed Securities [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0		0
Asset-backed Securities [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	3.1		1.4
Asset-backed Securities [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0		0
Commercial Paper [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	1.5		21.1
Commercial Paper [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0		0
Commercial Paper [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	1.5		21.1
Commercial Paper [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0		0
Time Deposits [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	44		5.7
Time Deposits [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0		5.7
Time Deposits [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	44		0
Time Deposits [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0		0
Money Market Funds [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	35.9		31.5
Money Market Funds [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	35.9		31.5
Money Market Funds [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0		0
Money Market Funds [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0		0
Cash Equivalents [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	105.2		65.7
Cash Equivalents [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	35.9		37.2
Cash Equivalents [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	69.3		28.5
Cash Equivalents [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0		0
US Treasury Securities \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	20.7		6
US Treasury Securities \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0
US Treasury Securities \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	20.7		6
US Treasury Securities \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]	0		0
Foreign Government Debt [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[8]			0
Municipal Obligations (Member) \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	18		23.1
Municipal Obligations (Member) \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0		0
Municipal Obligations (Member) \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	18		23.1
Municipal Obligations (Member) \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0		0
Foreign Government Obligations [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	13.6		13.5
Foreign Government Obligations [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0		0
Foreign Government Obligations [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	13.6		13.5
Foreign Government Obligations [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0		0
Corporate Debt Securities [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	674.2		699.3
Corporate Debt Securities [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0		0
Corporate Debt Securities [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	674.2		699.3
Corporate Debt Securities [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0		0
US Government Sponsored Agencies [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	293.7		230.7
US Government Sponsored Agencies [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0		0
US Government Sponsored Agencies [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	293.7		230.7
US Government Sponsored Agencies [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0		0
Asset-backed Securities [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	328.1		333.4
Asset-backed Securities [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0		0
Asset-backed Securities [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	328.1		333.4
Asset-backed Securities [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0		0
Short-term Investments [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	[4]	59.7		56.5
Debt Securities, Available-for-sale	[2]	1,327.6		1,300
Short-term Investments [Member] \| Municipal Obligations (Member) \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	18		23.1
Short-term Investments [Member] \| Foreign Government Obligations [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	13.6		13.5
Short-term Investments [Member] \| Corporate Debt Securities [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	674.2		699.3
Short-term Investments [Member] \| US Government Sponsored Agencies [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	293.7		230.7
Short-term Investments [Member] \| Asset-backed Securities [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	328.1		333.4
Other Investments [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[3]	1.4		1.2
Equity Securities	[4]	8,511.9		8,473.9
Restricted investment [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[3]	$ 5.6		$ 5.6

[1]The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets.[2]Available-for-sale investments are included in Short-term investments in the condensed consolidatedbalance sheets.[3]Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2023 December 31, 2022 Restricted investments $ 5.6 $ 5.6 Other investments 1.4 1.2 Total $ 7.0 $ 6.8 March 31, 2023 December 31, 2022 Short-term investments $ 59.7 $ 56.5 Other investments 8,511.9 8,473.9 Total $ 8,571.6 $ 8,530.4

2. Fair Value Measurements 3. C

2. Fair Value Measurements 3. Contingent Consideration (Details) - USD ($) $ in Millions	Mar. 31, 2023	[1]	Dec. 31, 2022	Aug. 03, 2022
Curiosity Diagnostics
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				$ 70
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	$ 36.4		$ 35.6
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	$ 36.4		$ 35.6

[1]Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. Changes in the fair value of contingent consideration are included in Selling, general and administrative expenses in our condensed consolidated statements of income (loss).

2. Foreign Exchange Forward Con

2. Foreign Exchange Forward Contracts (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)	[1],[2]
Forward foreign exchange contract to sell foreign currency [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	$ 719.5
Loss on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	0.2
Forward foreign exchange contract to purchase foreign currency [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	84.9
Loss on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	$ 0.2

[1]Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.[2]Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.

2. Available-for-Sale Investmen

2. Available-for-Sale Investments (Details) - USD ($) $ in Millions		Mar. 31, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	[1]	$ 1,344.1
Debt Securities, Available-for-sale	[1]	1,327.6
Fair Value, Recurring [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	1,327.6	$ 1,300
Fair Value, Recurring [Member] \| Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	[1]	1,344.1	1,320.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[1]	0.9	0.3
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[1]	(17.4)	(20.9)
Debt Securities, Available-for-sale, Allowance for Credit Loss	[1]	0	0
Debt Securities, Available-for-sale	[1]	1,327.6	1,300
Fair Value, Recurring [Member] \| Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	674.2	699.3
Fair Value, Recurring [Member] \| Corporate Debt Securities [Member] \| Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	[1]	682.8	709.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[1]	0.4	0.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[1]	(9)	(10.8)
Debt Securities, Available-for-sale, Allowance for Credit Loss	[1]	0	0
Debt Securities, Available-for-sale	[1]	674.2	699.3
Fair Value, Recurring [Member] \| Municipal obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	18	23.1
Fair Value, Recurring [Member] \| Municipal obligations [Member] \| Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	[1]	18.2	23.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[1]	0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[1]	(0.2)	(0.3)
Debt Securities, Available-for-sale, Allowance for Credit Loss	[1]	0	0
Debt Securities, Available-for-sale	[1]	18	23.1
Fair Value, Recurring [Member] \| US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	293.7	230.7
Fair Value, Recurring [Member] \| US Government Sponsored Agencies [Member] \| Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	[1]	295.9	233.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[1]	0.2	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[1]	(2.4)	(3.2)
Debt Securities, Available-for-sale, Allowance for Credit Loss	[1]	0	0
Debt Securities, Available-for-sale	[1]	293.7	230.7
Fair Value, Recurring [Member] \| Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	13.6	13.5
Fair Value, Recurring [Member] \| Foreign Government Obligations [Member] \| Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	[1]	13.8	13.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[1]	0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[1]	(0.2)	(0.3)
Debt Securities, Available-for-sale, Allowance for Credit Loss	[1]	0	0
Debt Securities, Available-for-sale	[1]	13.6	13.5
Fair Value, Recurring [Member] \| Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	328.1	333.4
Fair Value, Recurring [Member] \| Asset-backed Securities [Member] \| Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	[1]	333.4	339.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[1]	0.3	0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[1]	(5.6)	(6.3)
Debt Securities, Available-for-sale, Allowance for Credit Loss	[1]	0	0
Debt Securities, Available-for-sale	[1]	$ 328.1	$ 333.4

[1]Available-for-sale investments are included in Short-term investments in the condensed consolidatedbalance sheets.

2. Amortized Cost and Fair Valu

2. Amortized Cost and Fair Value of Debt Securities (Details) $ in Millions	Mar. 31, 2023 USD ($)	[1]
Fair Value Disclosures [Abstract]
Mature in less than one year	$ 412.5
Mature in one to five years	777.2
Mature in more than five years	154.4
Total Amortized Cost	1,344.1
Mature in less than one year	409.1
Mature in one to five years	767.7
Mature in more than five years	150.8
Debt Securities, Available-for-sale	$ 1,327.6

[1]Available-for-sale investments are included in Short-term investments in the condensed consolidatedbalance sheets.

2. Fair Value Financial Instrum

2. Fair Value Financial Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest Receivable, Current	$ 14.8	$ 11.6
Ordinary voting shares [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment ownership percentage	38%
Investment Owned, Balance, Shares	12,987,900
Preference shares [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment ownership percentage	28%
Investment Owned, Balance, Shares	9,588,908

2. Fair Value Measurements (Det

2. Fair Value Measurements (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2023	Dec. 31, 2022
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Equity Securities, FV-NI, Unrealized Loss		$ (20.1)
Fair value of Appreciation rights
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]
Investment Owned, Unrecognized Unrealized Appreciation	[1]	10.2
Short-term Investments [Member] \| Fair Value, Recurring [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[2]	0.9	$ 0.3
Short-term Investments [Member] \| Fair Value, Recurring [Member] \| Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[2]	$ 0.4	$ 0.2

[1]The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets.[2]Available-for-sale investments are included in Short-term investments in the condensed consolidatedbalance sheets.

2. Fair Value Measurements (D_2

2. Fair Value Measurements (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Interest Receivable, Current	$ 14.8	$ 11.6

4. Intangible Assets, Goodwil_3

4. Intangible Assets, Goodwill and Other (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Goodwill [Line Items]
Goodwill	$ 743,000	$ 741,700
Accumulated impairment loss	(335,200)	(335,200)
Goodwill, net	407,757	$ 406,488
Goodwill, Acquired During Period	400
Goodwill, Foreign Currency Translation Gain (Loss)	900
Goodwill, Period Increase (Decrease)	$ 1,300
Customer Relationships [Member]
Goodwill [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	5 years	5 years
Clinical Diagnostics [Member]
Goodwill [Line Items]
Goodwill	$ 409,700	$ 408,400
Accumulated impairment loss	(293,400)	(293,400)
Goodwill, net	116,300	115,000
Goodwill, Acquired During Period	400
Goodwill, Foreign Currency Translation Gain (Loss)	900
Goodwill, Period Increase (Decrease)	1,300
Life Science [Member]
Goodwill [Line Items]
Goodwill	333,300	333,300
Accumulated impairment loss	(41,800)	(41,800)
Goodwill, net	291,500	$ 291,500
Goodwill, Acquired During Period	0
Goodwill, Foreign Currency Translation Gain (Loss)	0
Goodwill, Period Increase (Decrease)	$ 0

4. Intangible Assets, Goodwil_4

4. Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Acquired Finite-Lived Intangible Assets [Line Items]
Goodwill, Acquired During Period	$ 0.4
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	556.4		$ 553.5
Accumulated Amortization	(421.2)		(412.4)
Net Carrying Amount	135.2		141.1
Amortization [Abstract]
Amortization expense	6	$ 6.3
Intangible Assets, Gross (Excluding Goodwill)	$ 749		$ 744.5
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	5 years		5 years
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 105.7		$ 104.7
Accumulated Amortization	(92.2)		(89.9)
Net Carrying Amount	$ 13.5		$ 14.8
Know How [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	2 years 6 months		2 years 9 months 18 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 167.3		$ 166.2
Accumulated Amortization	(156.1)		(153.9)
Net Carrying Amount	$ 11.2		$ 12.3
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	12 years 8 months 12 days		12 years 9 months 18 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 211.9		$ 211.1
Accumulated Amortization	(124.6)		(121.6)
Net Carrying Amount	$ 87.3		$ 89.5
Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	5 years 7 months 6 days		5 years 9 months 18 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 59		$ 59
Accumulated Amortization	(39.5)		(38.5)
Net Carrying Amount	$ 19.5		$ 20.5
Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	6 years 3 months 18 days		6 years 7 months 6 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 6.1		$ 6.1
Accumulated Amortization	(4.5)		(4.5)
Net Carrying Amount	$ 1.6		$ 1.6
Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	3 years		3 years 1 month 6 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 6.4		$ 6.4
Accumulated Amortization	(4.3)		(4)
Net Carrying Amount	2.1		2.4
In Process Research and Development [Member]
Amortization [Abstract]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 192.6		$ 191

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Total inventories	$ 752,937	$ 719,316
Inventory, Raw Materials, Net of Reserves	233,700	228,800
Inventory, Work in Process, Net of Reserves	224,200	220,900
Inventory, Finished Goods, Net of Reserves	$ 295,000	$ 269,600

6. Supplemental Cash Flow Inf_2

6. Supplemental Cash Flow Information - (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Net Income Attributable to Parent	$ 68,962	$ (3,367,347)
Depreciation and amortization	35,600	33,400
Reduction in the carrying amount of right-of-use assets	10,000	10,000
Share-based Compensation	16,600	13,500
(Gains) losses from change in fair market value of equity securities and loan receivable	17,500	4,545,100
Payments of operating lease liabilities	(9,900)	(9,500)
Decrease in accounts receivable	(1,400)	(46,800)
Decrease (increase) in inventories	(30,100)	(35,500)
Increase in other current assets	(16,000)	(33,800)
Decrease in accounts payable and other current liabilities	8,200	(38,900)
Increase in income taxes payable	10,400	7,800
Increase in deferred income taxes	(13,900)	(1,027,800)
Increase in other long term liabilities	2,500	200
Other	(400)	100
Net cash provided by operating activities	98,119	50,494
Noncash or Part Noncash Acquisition, Fixed Assets Acquired	8,400	1,500
Noncash or Part Noncash Acquisition, Investments Acquired	6,300	13,200
Noncash or Part Noncash Acquisition, Accounts Receivable Acquired	$ 0	$ 2,000

5. Long-Term Debt (Details)

5. Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Other Long-term Debt, Current	$ 500	$ 500
Long-term debt, net of current maturities	1,198,005	1,197,716
Finance Lease Obligations [Member] \| Finance Leases and Other Debt [Member]
Debt Instrument [Line Items]
Other Long-term Debt	10,500	10,600
Senior Notes \| Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	(12,000)	(12,400)
Long-term debt	1,188,000	1,187,600
Senior Notes \| 3.3%, Senior Notes due 2027
Debt Instrument [Line Items]
Senior Notes, Noncurrent	400,000	400,000
Senior Notes \| 3.7%, Senior Notes due 2032
Debt Instrument [Line Items]
Senior Notes, Noncurrent	$ 800,000	$ 800,000

6. Accumulated Other Comprehe_3

6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	$ (466,822)
Total other comprehensive income (loss) net of tax	58,470	$ (132,303)
Ending balance, Accumulated other comprehensive income	(408,352)
Other (income) expense, net	(50,431)	(32,597)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	(466,500)	(170,500)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	55,400	(128,700)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	0
Other Comprehensive Income (Loss), Tax	(200)	100
Total other comprehensive income (loss) net of tax	55,200	(128,600)
Ending balance, Accumulated other comprehensive income	(411,300)	(299,100)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	10,000	(10,900)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	100	400
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	100
Other Comprehensive Income (Loss), Tax	100	(100)
Total other comprehensive income (loss) net of tax	100	300
Ending balance, Accumulated other comprehensive income	10,100	(10,600)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	(10,300)	5,800
Other Comprehensive Income (Loss), before Reclassifications, before Tax	4,000	(5,200)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	(200)
Other Comprehensive Income (Loss), Tax	(1,000)	1,200
Total other comprehensive income (loss) net of tax	3,200	(4,000)
Ending balance, Accumulated other comprehensive income	(7,100)	1,800
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	(466,800)	(175,600)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	59,500	(133,500)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	(100)
Other Comprehensive Income (Loss), Tax	(1,100)	1,200
Total other comprehensive income (loss) net of tax	58,500	(132,300)
Ending balance, Accumulated other comprehensive income	$ (408,300)	$ (307,900)

7. Earnings Per Share (Details)

7. Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Basic weighted average shares outstanding	29,596	29,933
Effect of potentially dilutive stock options and restricted stock awards	151	0
Diluted weighted average common shares	29,747	29,933
Anti-dilutive shares	94	550

8. Other Income and Expenses (D

8. Other Income and Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Interest and investment income	$ (50,300)	$ (32,200)
Net realized (gain) loss on investments	700	0
Other Nonoperating (Income)	(800)	(400)
Other (income) expense, net	$ (50,431)	$ (32,597)

9. Income Taxes (Details)

9. Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
9. Income Taxes (Details) - USD ($) $ in Millions	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Effective tax rate	18.70%	22.90%
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	$ 17.6
Unrecognized Tax Benefits	$ 87.2		$ 85.5

Segment Reporting (Details)

Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended
Segment Reporting (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Net sales	$ 676,844	$ 700,062
Operating Income (Loss)	61,913	146,408
Net Assets, Segment	13,667,414		$ 13,501,666
Life Science [Member]
Segment Reporting Information [Line Items]
Net sales	323,600	347,200
Operating Income (Loss)	35,700	89,600
Clinical Diagnostics [Member]
Segment Reporting Information [Line Items]
Net sales	352,100	351,800
Operating Income (Loss)	26,300	57,100
Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales	1,100	1,100
Operating Income (Loss)	$ (100)	$ (300)

10. Segment Information Segme_3

10. Segment Information Segment Profit Reconciliations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Marketable Securities, Unrealized Gain (Loss)	$ (17,525)	$ (4,545,117)
Net sales	676,844	700,062
Operating Income (Loss)	61,913	146,408
Interest expense	12,337	4,048
Foreign Currency Transaction Gain (Loss), before Tax	2,347	2,128
Other Nonoperating Income (Expense)	50,431	32,597
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	84,829	(4,368,032)
Life Science [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	323,600	347,200
Operating Income (Loss)	35,700	89,600
Other Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	1,100	1,100
Operating Income (Loss)	(100)	(300)
Clinical Diagnostics [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	352,100	351,800
Operating Income (Loss)	26,300	57,100
Operating Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating Income (Loss)	61,900	146,400
Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Debt and Equity Securities, Unrealized Gain (Loss)	(17,500)	(4,545,100)
Foreign Currency Gain (Loss) [Member] \| Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax	2,300	2,100
Other Nonoperating Income (Expense) [Member] \| Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Other Nonoperating Income (Expense)	50,400	32,600
Interest Expense \| Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Interest expense	$ (12,300)	$ (4,000)

10. Segment Information Segme_4

10. Segment Information Segment Asset Reconciliation (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 13,667,414	$ 13,501,666

10. Segment Information Revenue

10. Segment Information Revenue by country (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting [Abstract]
Net sales	$ 676,844	$ 700,062
Revenue by country [Line Items]
Net sales	676,844	700,062
Europe [Member]
Segment Reporting [Abstract]
Net sales	204,800	218,900
Revenue by country [Line Items]
Net sales	204,800	218,900
UNITED STATES
Segment Reporting [Abstract]
Net sales	297,000	282,500
Revenue by country [Line Items]
Net sales	297,000	282,500
Asia Pacific [Member]
Segment Reporting [Abstract]
Net sales	135,800	160,900
Revenue by country [Line Items]
Net sales	135,800	160,900
Americas [Member]
Segment Reporting [Abstract]
Net sales	39,200	37,800
Revenue by country [Line Items]
Net sales	$ 39,200	$ 37,800

14. Restructuring Costs (Detail

14. Restructuring Costs (Details) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended		26 Months Ended
14. Restructuring Costs (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 37,300	$ 37,300		$ 37,300
Cost of goods sold		314,427	$ 297,427
Accounts Payable and Accrued Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	36,700	36,700		36,700
Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	600	600		600
Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment		9,100
Cost of Sales [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment		300
Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment		4,200
European Reorganization
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	23,600	23,600		23,600	$ 31,600
Restructuring Charges				67,300
Payments for Restructuring		(7,000)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss		300
Restructuring Reserve, Accrual Adjustment		(1,300)
European Reorganization \| Life Science [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	800	800		800	1,900
Payments for Restructuring		(900)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss		100
Restructuring Reserve, Accrual Adjustment		(300)
European Reorganization \| Clinical Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	22,800	22,800		22,800	29,700
Payments for Restructuring		(6,100)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss		200
Restructuring Reserve, Accrual Adjustment		(1,000)
European and American Reorganization
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	13,700	13,700		13,700	0
Restructuring Charges	14,900	14,900
Payments for Restructuring		(1,500)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss		300
European and American Reorganization \| Life Science [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	6,600	6,600		6,600	0
Restructuring Charges		7,200
Payments for Restructuring		(700)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss		100
European and American Reorganization \| Clinical Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 7,100	7,100		$ 7,100	$ 0
Restructuring Charges		7,700
Payments for Restructuring		(800)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss		$ 200

13. Leases (Details)

13. Leases (Details) - USD ($) $ in Thousands	3 Months Ended
13. Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Operating Lease, Cost	$ 15,800	$ 14,300
Finance Lease, Right-of-Use Asset, Amortization	100	100
Finance Lease, Interest Expense	200	200
Finance Lease Cost	300	300
Operating Lease, Payments	9,900	9,500
Finance Lease, Interest Payment on Liability	200	200
Finance Lease, Principal Payments	100	100
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	2,200	$ 5,500
Operating lease right-of-use assets	$ 174,096		$ 180,952
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities		Other current liabilities
Current operating lease liabilities	$ 36,149		$ 36,336
Operating lease liabilities	147,040		153,597
Operating Lease, Liability	183,100		189,900
Finance Lease, Right-Of-Use Asset, before Accumulated Amortization	11,900		11,900
Finance Lease, Right-Of-Use Asset, Accumulated Amortization	5,600		5,500
Finance Lease, Right-Of-Use Asset, after Accumulated Amortization	6,300		6,400
Finance Lease, Liability, Current	500		500
Finance Lease, Liability, Noncurrent	10,000		10,100
Finance Lease, Liability	$ 10,500		$ 10,600
Operating Lease, Weighted Average Remaining Lease Term	7 years		7 years
Finance Lease, Weighted Average Remaining Lease Term	14 years		15 years
Operating Lease, Weighted Average Discount Rate, Percent	3.10%		3%
Finance Lease, Weighted Average Discount Rate, Percent	6.40%		6.30%
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 31,100
Finance Lease, Liability, Payments, Remainder of Fiscal Year	1,200
Lessee, Operating Lease, Liability, to be Paid, Year One	37,100
Finance Lease, Liability, to be Paid, Year One	1,200
Lessee, Operating Lease, Liability, Payments, Due Year Two	33,600
Finance Lease, Liability, Payments, Due Year Two	1,100
Lessee, Operating Lease, Liability, Payments, Due Year Three	26,300
Finance Lease, Liability, Payments, Due Year Three	1,100
Lessee, Operating Lease, Liability, Payments, Due Year Four	21,100
Finance Lease, Liability, Payments, Due Year Four	1,100
Lessee, Operating Lease, Liability, Payments, Due after Year Five	56,600
Finance Lease, Liability, Payments, Due after Year Five	11,600
Lessee, Operating Lease, Liability, Payments, Due	205,800
Finance Lease, Liability, Payment, Due	17,300
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(22,700)
Finance Lease, Liability, Undiscounted Excess Amount	$ (6,800)
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term	16 years